SEREVENT DISKUS (50MCG/DOSE) POWDER

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

SALMETEROL (SALMETEROL XINAFOATE)

Доступна с:

GLAXOSMITHKLINE INC

код АТС:

R03AC12

ИНН (Международная Имя):

SALMETEROL

дозировка:

50MCG

Фармацевтическая форма:

POWDER

состав:

SALMETEROL (SALMETEROL XINAFOATE) 50MCG

Администрация маршрут:

INHALATION

Штук в упаковке:

60 DOSE

Тип рецепта:

Prescription

Терапевтические области:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Обзор продуктов:

Active ingredient group (AIG) number: 0126960002; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2001-07-04

Характеристики продукта

_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SEREVENT DISKUS
salmeterol xinafoate dry powder for inhalation
50 mcg salmeterol (as the xinafoate salt)/blister
Bronchodilator
(beta2-adrenergic stimulant)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Initial Approval:
October 25, 1994
Date of Revision:
March 2, 2021
Submission Control No: 243734
_2021 GSK group of companies or its licensor_
_ _
_Trademarks are owned by or licensed to the GSK group of companies _
_ _
_Page 2 of 49_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE
NOT LISTED.
PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 4
1
INDICATIONS ...............................................................................................................
4
1.1
Pediatrics
...............................................................................................................
5
1.2
Geriatrics
...............................................................................................................
5
2
CONTRAINDICATIONS ..............................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................ 6
4
DOSAGE AND ADMINISTRATION ...........................................................................
7
4.1 Dosing Considerations
...............................................................................................
7
4.2 Recommended Dose and Dosage Adjustment
............................................................ 8
4.4 Administration
...........................................................................................................
9
4.5 Missed Dose
..............................................................................................................
9
5
OVERDOSAGE ....................................................................................